by Harriet Boyd | Nov 2024 | Blogs
Synthetic Biology Technologies for Antibody Discovery Imagine bypassing the lengthy traditional immunization process and tapping into the antibody diversity equivalent of over a million llamas – right at your fingertips. At Isogenica, our libraries, built with...
by Harriet Boyd | Oct 2024 | Blogs
Nanobody or VHH – What’s the difference? In the realm of biotechnology and medicine, the terms nanobody and VHH are often used interchangeably to describe single-domain antibodies. These small-format versions of traditional antibodies have grown as...
by Harriet Boyd | Sep 2024 | Blogs
Tools for ADC drug discovery – screening VHHs with pre-engineered C-terminal cysteine handles In the fast-paced world of biotechnology, innovation often stems from taking smart, calculated risks. At Isogenica, we are used to running unusual antibody drug discovery...
by Harriet Boyd | Sep 2024 | Blogs
Specific Antibodies to Difficult Targets: How to find the needles in the haystack Peptides, often small and unstructured, are some of the most difficult targets in antibody discovery. Here, we recount how we tweaked our approach to mining our vast VHH libraries to...
by Harriet Boyd | Jul 2024 | Blogs
Advantages of using VHH antibodies for CAR engineering Since the first anti-CD19 CAR-T cell therapy was approved in 2017, there’s been an explosion of interest in using engineered immune cells to treat cancer. CAR constructs consist of an external antibody-based...
by Harriet Boyd | Jul 2024 | Blogs
Small antibodies, big libraries Why size matters when it comes to synthetic VHH discovery If you work in the antibody discovery space, you’ve probably considered using synthetic libraries at some point. You might have heard about the speed at which they can generate...